a randomized controlled trial AI escitalopram in treatment of persistent somatoform pain disorder

OBJECTIVE To study the efficacy and safety of AI escitalopram in treatment of persistent somatoform pain disorder.METHODS A randomized,open design and out-patient in treatment of persistent somatoform pain disorder patients were randomly divided into two groups.40 cases in the treatment group(escitalopram),and 40 cases in the control group(venlafaxine),the course of treatment was 6 weeks.The treatment efficacy was assessed before and after treatment at the time of first,second,fourth and sixth weekends.The Hamilton depression scale(HAMD),Hamilton anxiety scale(HAMA),side effects symptoms scale(TESS)were used to assess the efficacy.RESULTS The escitalopram and venlafaxine therapy has efficacy in treatment of persistent somatoform pain disorder.The remission times of consciously symptoms in the experimental and control groups were shortened,and the clinical efficacy was obvious.HAMD and HAMA score did not show significant difference.The efficacy rate of the two groups within 6 weeks were(to reduce fraction = 50% of the standard):80% in the treated groups,and 85% inthe control group,P﹥0.05.The adverse reaction scores in the first weekend of the control Group were significantly higher than those of the treatment group,and there was significant difference between the two groups(P﹤0.01).CONCLUSION The persistent somatoform pain disorder still existed in patients with depression and anxiety,but AI escitalopram with 10 mg/day has fast,low incidence of adverse reactions,and better security.